| 摘要 |
Renal disorders caused by the administration of cisplatin are ameliorated by administering an antibody having an inhibitory effect on type II phospholipase A2. A monoclonal antibody capable of inhibiting the type II phospholipase A2 activity or proteins or peptides containing a part of the antibody and having the same inhibitory effect are capable of depressing the nephrotoxicity, which is the most remarkable side effect of cisplatin and restricts the dose of cisplatin, and, therefore, are usable as drugs for ameliorating the renal disorders thus caused. |
